Clinical trials: Acute Dyspnea
Respiratory Insufficiency, Dyspnea
HVNI Ambulation Feasibility Study
The pilot/feasibility study evaluates the ability of High Velocity Nasal Insufflation (HVNI) therapy to facilitate ambulation and mobilization in patients experiencing shortness of breath, as compared to simple oxygen therapy.
- Trial name
- NCT03885726
- Testing
- Precision Flow Plus, Treatment as Usual
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Vapotherm, Inc.
Dyspnea, Acute Decompensated Heart Failure
Evaluation of Cardiopulmonary Diseases by Ultrasound
Historically, ultrasound imaging of the lung parenchyma has been challenging because of the high total ultrasound energy attenuation and scattering by the air in the lungs.
- Trial name
- NCT02248831
- Testing
- Recording Doppler ultrasound signals noninvasively
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Echosense Ltd.
Acute Decompensated Heart Failure
Gas Exchange for Predicting Hospital Heart Failure Readmissions
To determine whether, and if so, which gas exchange parameters measured on the Shape-HF Cardiopulmonary Exercise Testing System predict 30 and 180 day re-hospitalization in subjects discharged from hospitalization for an episode…
- Trial name
- NCT01960218
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Shape Medical Systems, Inc.
Post-COVID-19 Syndrome, COVID-19
Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome
Reports of long-lasting symptoms of COVID-19 are increasing, but little is known about the prevalence of risk factors or whether it is possible to predict a prolonged course at disease onset.
- Conditions
- Post-COVID-19 Syndrome, COVID-19, Dyspnea, Fatigue
- Trial name
- NCT06437210
- Testing
- Viusid Oral Solution
- Where
- Colombia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Catalysis SL
Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout
Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel
The purpose of the study is to describe patient characteristics and drug usage among patients that are prescribed ticagrelor for the first time and to compare them with patients who are prescribed clopidogrel and prasugrel for…
- Trial name
- NCT01276275
- Testing
- Risk of selected safety events
- Where
- Sweden
- Volunteers
- 7,200 people
- Sponsor
- AstraZeneca
Dyspnea, Hypertension
Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF
The purpose of this study is to evaluate dyspnea improvement and other parameters of efficacy and safety in acute heart failure (AHF) patients receiving an intravenous (IV) infusion of clevidipine in comparison to standard of…
- Conditions
- Dyspnea, Hypertension, Acute Heart Failure
- Trial name
- PRONTO II (NCT04592380)
- Testing
- Stage 1: Clevidipine (double-blinded), Stage 2: Clevidipine (open-label), Stage 2: Standard of Care (open-label)
- Where
- 9 sites in United States
- Sponsor
- The Medicines Company
Heart Failure, Congestive
Heart Failure Registry
The purpose of this registry is to compile a large clinical database on the medical management of patients hospitalized with acute heart failure, using information collected from acute care hospitals across the United States.
- Trial name
- NCT00530426
- Volunteers
- 150,000 people
- Sponsor
- Scios, Inc.
Acute Respiratory Distress Syndrome, Coronavirus
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical…
- Conditions
- Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure
- Trial name
- VANGARD (NCT04433546)
- Testing
- Pemziviptadil (PB1046), Low Dose (10 mg) Control
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Dyspnea, Acute Heart Failure Syndrome
Precision of IMED-4 Lung Fluid Measurements
The purpose of this study is to determine if IMED-4 recordings have sufficient precision to detect a clinically significant change in lung fluid status in acute heart failure syndrome with pulmonary congestion.
- Conditions
- Dyspnea, Acute Heart Failure Syndrome, Pulmonary Congestion
- Trial name
- NCT02187770
- Testing
- IMED-4
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- Intersection Medical, Inc.
ADHF
Evaluation of the Diagnostic Value of the TPD System in Determining ADHF Causing Acute Dyspnea
The objective of this study is to evaluate Lung Doppler signals (LDS) among patients presenting to the emergency department with acute dyspnea, in order to determine the diagnostic value of this non-invasive method to…
- Trial name
- NCT03998410
- Testing
- Lung Doppler Signals
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- Echosense Ltd.
Hypercapnic Respiratory Failure, Chronic Obstructive Pulmonary Disease
Clinical Stabilization of Hypercapnia: NIPPV v HVNI
This study will evaluate the ability of High Velocity Nasal Insufflation [HVNI] to effect ventilation and related physiologic responses in hypercapnic patients when compared to noninvasive positive pressure ventilation [NIPPV].
- Conditions
- Hypercapnic Respiratory Failure, Chronic Obstructive Pulmonary Disease, Dyspnea, Hypercapnic Acidosis
- Trial name
- HYPERACT (NCT04709562)
- Testing
- High Velocity Nasal Insufflation (HVNI), Noninvasive Positive Pressure Ventilation (NIPPV)
- Where
- 7 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Vapotherm, Inc.
Shortness of Breath, Heart Failure
Biomarkers in Acute Heart Failure
Primary Objectives 1. Mid Region pro Adrenomedullin (MR-proADM) is superior to BNP for the prognosis of heart failure (HF) patients and adds incremental value in predicting outcomes for patients presenting to the Emergency…
- Trial name
- BACH (NCT00537628)
- Where
- 15 sites in United States, Germany and 6 more
- Volunteers
- 1,641 people
- Sponsor
- Brahms AG
Longitudinal Observational Study With 6 Months Follow-up
Longitudinal Observational Study for mIddle Term Follow-up Patients Admitted for Acute Dyspnea in TunIsia
The purpose of the SIDI study is to follow, few months after discharge from the hospital, the patients admitted to the 3 emergency departments in Tunisia for acute dyspnea and to determine the proportion and the factors favoring…
- Trial name
- SIDI (NCT04947358)
- Where
- Tunisia
- Volunteers
- 180 people
- Sponsor
- S Form Pharma
Pneumonia, Interstitial Plasma Cell, Pneumocystis Carinii Pneumonia
DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)
The purpose of this study is to demonstrate the non-inferiority of pafuramidine maleate (DB289)versus trimethoprim-sulfamethoxazole (TMP-SMX)for the treatment of mild to moderately severe Pneumocystis pneumonia (PCP).
- Conditions
- Pneumonia, Interstitial Plasma Cell, Pneumocystis Carinii Pneumonia, Pneumonia, Pneumocystis Carinii, HIV Infections
- Trial name
- NCT00302341
- Testing
- Pafuramidine maleate (DB289), Trimethoprim-Sulfamethoxazole (TMP-SMX)
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Immtech Pharmaceuticals, Inc
ARDS
MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)
Multicenter investigation featuring an open-label lead-in followed by a double blinded, randomized, placebo-controlled Phase 2/3 part to evaluate the safety and efficacy of MultiStem therapy in subjects with moderate to severe…
- Trial name
- MACoVIA (NCT04367077)
- Testing
- MultiStem
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Healios K.K.
Severe Dyspnea, CAPD
BIOmarkers of Dyspnea IN Emergency Room
The purpose of this study is to evaluate the capacity of some novels biomarkers Procalcitonin (PCT), Midregional Proadrenomedullin (MR pro ADM), Midregional pro-atrial natriuretic peptide (MR pro ANP), Copeptin (CT pro arginine…
- Conditions
- Severe Dyspnea, CAPD, AE COPD, Acute Heart Failure
- Trial name
- BIODINER (NCT01227317)
- Testing
- Prognostic value of Biomarkers
- Where
- France
- Volunteers
- 444 people
- Sponsor
- ThermoFisher Scientific Brahms Biomarkers France
Heart Failure
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)
The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart…
- Trial name
- NCT01300013
- Testing
- Omecamtiv mecarbil
- Where
- 150 sites in United States, Australia and 17 more
- Volunteers
- 614 people
- Sponsor
- Cytokinetics
Bronchitis, Cough
Treatment of Respiratory Tract Infection and/or Acute Bronchitis With Ectoin Inhalation Solution
This observational, non-interventional multicentric study compares the inhalation therapy on patients suffering on respiratory tract infections and/or acute bronchitis between Ectoin inhalation solution and Pari NaCl (0.9%)…
- Conditions
- Bronchitis, Cough, Sputum, Cellular Atypia, Dyspnoea
- Trial name
- NCT02632851
- Where
- Germany
- Volunteers
- 135 people
- Sponsor
- Bitop AG
Covid19, Postviral Syndrome
ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome
This is a Phase I/II trial to evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EV), ExoFlo, as treatment for Post-Acute COVID-19 and Chronic…
- Conditions
- Covid19, Postviral Syndrome, Dyspnea
- Trial name
- NCT05116761
- Testing
- Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles, Saline
- Sponsor
- Direct Biologics, LLC
Heart Decompensation
A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure
The purpose of this study is to find out if nesiritide (a human B-type natriuretic peptide/hBNP) as compared to placebo, plus the usual treatment for acute decompensated heart failure, helps to improve breathing difficulties…
- Trial name
- NCT00475852
- Testing
- Nesiritide
- Where
- 328 sites in United States, Argentina and 26 more
- Volunteers
- 7,141 people
- Sponsor
- Scios, Inc.